Phase 2Not yet recruitingAge-related condition
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD (EXPD-101-201)
- Sponsor
- Expedition Therapeutics Inc. (Industry)
- Enrolment
- 183 planned
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD) exacerbations; Chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease exacerbation
- Interventions
- EXPD-101
- Ages
- adults, older adults
- Registry
- CTIS2026-525216-34-00, PACTR202609911768910
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To evaluate the effect of EXPD-101 compared with placebo on annualized rate of moderate and severe COPD exacerbations over 52 weeks of treatment. To assess the safety and tolerability of EXPD-101 compared with placebo.
Primary outcomes
- Annualized rate of moderate and severe COPD exacerbations over 52 weeks of treatment, Adverse events, vital signs, ECGs, physical exams, and clinical laboratory evaluations.
History
Last registry update
Registered